AGOVIRAX® – clinically proven protection against the most common cold viruses.
The active substance iota-carrageenan forms a protective layer on the nasal and oral mucosa. This serves as a physical barrier that effectively prevents binding and entry of the respiratory viruses, including coronaviruses, into the cells.
AGOVIRAX® mode of action
Common cold and flu-like illnesses can be caused by more than 200 virus strains.6
These viruses usually enter the human body through nose. Viruses then attach themselves to the mucous membrane and infect mucosal cells where they multiply and spread. This results in the typical symptoms of a cold, such as a stuffed or runny nose, sore throat, headache, cough, etc.6
The active ingredient, iota-carrageenan, has a dual positive effect.
- Iota-carrageenan creates a protective barrier against common cold viruses. It encases the viruses that cause colds and prevents them from binding to the mucous membrane. Thereby, the multiplication and spread of respiratory viruses is reduced and infection is stopped.7,8,9
- AGOVIRAX® forms a long-lasting moisturising, protective film on the mucosal surface. This film serves as a physical barrier against external influences and also supports the body’s natural defences against viruses.8,9,10
What does AGOVIRAX® contain?
It is a clear, colourless, viscous solution without odour. 1 ml solution contains 1.2 mg iota-carrageenan (Carragelose®), 0.4 mg kappa-carrageenan, sodium chloride and purified water.
The active substance of AGOVIRAX®, iota-carrageenan, is derived from edible species of red seaweeds.
Scientific studies confirmed that iota-carrageenan is a potent inhibitor of virus infectivity and acts 10 times better compared to other types of carrageenan.12
Later clinical studies with adults and children confirmed broad spectrum antiviral efficacy and therapeutic effects of iota-carrageenan.
AGOVIRAX® has localised effects because iota-carrageenan is not absorbed by the cells of the nasopharyngeal mucosa. It has no other side effects besides very rare cases of hypersensitivity.
AGOVIRAX® mode of action
Dosage and method of administration of AGOVIRAX® nasal spray
At the first signs of a flu-like infection (e.g., throat pain, tingling, or runny nose, etc.), one spray should be administered at least three times daily into each nostril. Treatment should be initiated as early as possible after the onset of the first cold symptoms and continued until the symptoms have subsided. If fever develops or there is no improvement after one week of treatment, a doctor should be consulted.
20 ml bottle with spray pump;
1 spray = 0.14 ml of solution (142 sprays in total)
Dosage and method of administration of AGOVIRAX® lozenges
Take a lozenge several times a day, usually 3 to 6 times daily depending on the individual requirements. The total daily amount should not exceed six lozenges, otherwise potential laxative effects may occur.
Each box contains 16 lozenges.
AGOVIRAX® unique filter system
The AGOVIRAX® unique filter system guarantees the sterility of the solution even after repeated use.
The spray system was designed using the advanced technology, such as a metal-free fluid path, a vented system, a special filter membrane and tip-seal, safeguarding the product from contamination and allowing it to remain sterile for 12 months after first use.
Approved after rigorous microbiological testing – TSIT (Tip Seal Integrity Test) and CVIT (Closure Ventilation Integrity Test).